PDS Biotechnology Corporation (PDSB)
PDSB moved a median of -0.74% 30 minutes after news, and -0.62% by the close. How PDSB actually reacts to news — the realized, point-in-time move the market made, measured across 248 labeled events over the last three years with zero look-ahead.
PDSB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 42% | 247 |
| 30-min | -0.74% | 36% | 247 |
| 60-min | -0.45% | 42% | 247 |
| to close | -0.62% | 45% | 245 |
| Middle 50% of PDSB reactions | -2.74% to +1.05% |
|---|---|
| Median reaction (30-min) | -0.74% |
| Measured reactions | 248 |
Half of all PDS Biotechnology Corporation news events land between -2.74% and +1.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PDSB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PDSB's baseline. Nothing else.
Recent PDSB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K PDS Biotechnology Corp For: Oct 18 | SEC filing · Form 8-K | SEC EDGAR | -3.14% | — | |
| PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors | Press release | GlobeNewswire | -3.14% | — | |
| Form S-3 PDS Biotechnology Corp | SEC filing · Form S-3 | SEC EDGAR | -1.44% | -6.47% | |
| Form 8-K PDS Biotechnology Corp For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +2.66% | -9.13% | |
| PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases | Press release | GlobeNewswire | +2.66% | -9.13% | |
| Form 8-K PDS Biotechnology Corp For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | -6.38% | |
| Form 8-K PDS Biotechnology Corp For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -4.65% | +5.81% | |
| PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology | Press release | GlobeNewswire | -4.65% | +5.81% | |
| Form 8-K PDS Biotechnology Corp For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | -4.65% | +5.81% | |
| Form 8-K PDS Biotechnology Corp For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -11.93% | +19.04% | |
| PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors | Press release | GlobeNewswire | -4.97% | +37.67% | |
| Form 8-K PDS Biotechnology Corp For: Sep 07 | SEC filing · Form 8-K | SEC EDGAR | +27.75% | -36.98% | |
| PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks | Press release | GlobeNewswire | +27.75% | -36.98% | |
| Form 8-K PDS Biotechnology Corp For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +27.75% | -36.98% | |
| Form 8-K PDS Biotechnology Corp For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -3.49% | -0.04% | |
| Form 8-K PDS Biotechnology Corp For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -2.56% | +3.06% | |
| Form 8-K PDS Biotechnology Corp For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +0.26% | |
| Form 10-Q PDS Biotechnology Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.04% | +0.26% | |
| Form 8-K PDS Biotechnology Corp For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -4.13% | -3.64% | |
| PDS Biotech Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -4.13% | -3.64% | |
| Form 8-K PDS Biotechnology Corp For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -13.07% | -62.12% | |
| PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 | Press release | GlobeNewswire | -13.07% | -62.12% | |
| Form 8-K PDS Biotechnology Corp For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.54% | |
| Form EFFECT PDS Biotechnology Corp | SEC filing · Form EFFECT | SEC EDGAR | -0.70% | -7.55% | |
| Form S-3 PDS Biotechnology Corp | SEC filing · Form S-3 | SEC EDGAR | -2.47% | -3.71% | |
| Form ARS PDS Biotechnology Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +4.55% | |
| Form DEF 14A PDS Biotechnology Corp For: Aug 10 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +4.55% | |
| Form DEFA14A PDS Biotechnology Corp | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +4.55% | |
| Form 8-K PDS Biotechnology Corp For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +3.70% | -5.56% | |
| Form PRE 14A PDS Biotechnology Corp For: Aug 10 | SEC filing · Form PRE | SEC EDGAR | -4.54% | -3.03% | |
| Form 8-K PDS Biotechnology Corp For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | -1.28% | |
| Form 10-Q PDS Biotechnology Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.13% | -4.29% | |
| Form 8-K PDS Biotechnology Corp For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +19.82% | |
| PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update | Press release | GlobeNewswire | +0.90% | +19.82% | |
| PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results | Press release | GlobeNewswire | +1.84% | -1.85% | |
| Form 8-K PDS Biotechnology Corp For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +1.67% | |
| Form EFFECT PDS Biotechnology Corp | SEC filing · Form EFFECT | SEC EDGAR | -5.41% | -13.49% | |
| Form 10-K/A PDS Biotechnology Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.41% | -13.49% | |
| Form S-3/A PDS Biotechnology Corp | SEC filing · Form S-3 | SEC EDGAR | -0.46% | +3.54% | |
| Form 8-K PDS Biotechnology Corp For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +0.00% | |
| Form 8-K PDS Biotechnology Corp For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +5.62% | +27.10% | |
| PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial | Press release | GlobeNewswire | +5.62% | +27.10% | |
| Form 10-K PDS Biotechnology Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.54% | +12.04% | |
| Form 8-K PDS Biotechnology Corp For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -8.28% | -11.21% | |
| PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement | Press release | GlobeNewswire | -8.28% | -11.21% | |
| PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results | Press release | GlobeNewswire | +1.67% | +11.35% | |
| Form 8-K PDS Biotechnology Corp For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -2.58% | |
| Form 8-K PDS Biotechnology Corp For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +1.54% | +3.00% | |
| Form 8-K PDS Biotechnology Corp For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -4.89% | -8.73% | |
| PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval | Press release | GlobeNewswire | -4.89% | -8.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PDSB section they belong to.
Where else PDSB is measured.
PDSB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PDS Biotechnology Corporation's median reaction calculated?
Every labeled PDSB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 248 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of PDSB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PDSB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.